New Covid Vaccine Approved - But Not For Everyone
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The United States Food and Drug Administration (FDA) has approved another vaccine maker to create a shot to help prevent COVID-19, with caveats.
Newsweek has reached out to Novavax for a statement over email Sunday during non-working hours.
Why It Matters
COVID-19, the disease is caused by the SARS-CoV-2 virus, swept through the world in early 2020, causing lockdowns, hospitalization spikes, and millions of deaths.
Over seven million people have died from COVID-19 globally since the start of the pandemic in 2020, according to the World Health Organization (WHO).
Out of the 7,095,349 deaths worldwide, 1,223,101 are in the US alone, the most recorded COVID-19 deaths of any country, according to WHO.
What To Know
Novavax's vaccine - Adjuvanted -is approved only for those aged 65 and older or people aged 12 to 65 "who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19", according to a letter from the FDA released Friday.
"We are confident our well-tolerated vaccine represents an important alternative to mRNA COVID-19 vaccines for the U.S.," a press release from the company issued when they entered the vaccine for approval in April read.
This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the letter said.
The approval comes amid Robert Kennedy Jr.'s appointment as United States Secretary of Health and Human Services. He has been outspoken about his distrust of medicinal treatments, including vaccines.
Novavax makes the only protein-based COVID-19 vaccine, which operates differently from other vaccines that use messenger RNA (mRNA).
Those mRNA vaccines prompt the patient to produce small amounts of virus to help create an immune response while the Adjuvanted has a protein spike to create the coupled with a Matrix-M adjuvant to prompt an immune response.
The company submitted its product for approval on April 1 along with Phase 3 clinical trial data, the press release said.
Development of the Novavax COVID-19 vaccine has been ongoing since 2020.
A general view of Novavax vaccine vials as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.
A general view of Novavax vaccine vials as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.
Photo by PatrickData from the United States Centers for Disease Control and Prevention (CDC) shows that vaccines have had overall benefits including a decrease in hospitalization of about one third among adults with weakened immune systems.
What People Are Saying
Dr. Paul Offit, Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia told The New York Times: "I think the goal of Robert F. Kennedy Jr. is to make vaccines less available, more expensive, and more feared."
Michael Lin, MD PhD, Professor of Neurobiology & Bioengineering at Stanford University said in part on X, formerly Twitter: "Now the FDA added some odd condition that the vaccine is for those with conditions that increase risk of COVID complications. Given its better safety, it seems backward to put this on Novavax and not the RNA vaccines. But I'd hope you'd be allowed to self declare."
What Happens Next
Now that the FDA has approved, the CDC will have to release guidance on usage. Additionally, Novavax is required to provide data on people who receive the vaccine, including rates of myocarditis.
Clinical trials of the vaccine are still being done for different age groups.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
32 minutes ago
- Medscape
Where Do We Stand on COVID Vaccine Recommendations in 2025?
This transcript has been edited for clarity. This edition of Medicine Matters takes a closer look at the future of COVID vaccines for fall 2025. The current status of COVID vaccines can be best described as unclear. There is confusion, conflicts of interest, and chaos. A lot has happened, so here is a brief recap of major developments over the past few months. New COVID Vaccine Approvals and a New Vaccine Formula On May 22, the FDA announced the new COVID vaccine formula, a monovalent JN.1 lineage — preferably using the LP.8.1 strain. On May 16, the FDA fully licensed the Novavax COVID vaccine but limited its use to those 65 or older, and to those aged 12-64 years with at least one high-risk medical condition. Later in May, these same restrictions were applied to the approval of Moderna's new lower-dose mRNA COVID vaccine, mNEXSPIKE. FDA's 'New' Way of Evaluating COVID Vaccines On May 20, in a sounding board article in The New England Journal of Medicine , the FDA Commissioner, Martin Makary, MD, MPH, and the Center for Biologics Evaluation and Research Director, Vinay Prasad, MD, MPH, announced new changes on how FDA would evaluate COVID vaccines. Additional clinical trials, including placebo-controlled trials using a saline placebo, would be required. They said the FDA anticipates that it will make favorable risk-benefit findings for adults 65 or older and for those 6 months or older with one or more risk factors that put them at high risk for severe COVID outcomes. Both pregnancy and recent pregnancy were on their list of underlying medical conditions that increase a person's risk for severe COVID. HHS Secretary Kennedy Issues His Own COVID Vaccine Directive One week later, on May 27, HHS Secretary Kennedy issued his own directive and unilaterally removed COVID vaccines from the immunization schedule for healthy children and for pregnant women. He made this announcement on social media. No new evidence was cited to support this decision. Absent from this announcement was any representative from the CDC or ACIP. Kennedy's actions triggered the resignation of several key and well-respected CDC employees in the COVID vaccine space. I've served on ACIP's COVID vaccine work group since the beginning. Our work group had not been consulted. In fact, work group meetings had been suspended. ACIP Members Ousted Before June Meeting Updated COVID vaccine recommendations had been expected to be on the June ACIP meeting agenda. But on June 9, just 2 weeks prior to the June ACIP meeting, HHS Secretary Kennedy removed all 17 ACIP members and then replaced them with his own handpicked group of eight — many of whom have preconceived bias against vaccines. At the June meeting, there was not a vote on COVID vaccines. However, CDC staff did present updates on COVID epidemiology. Here are some highlights: Most pediatric hospitalizations (57%) occur in children less than 2 years of age. Most hospitalized children in this age group have no underlying medical conditions. Rates of COVID-associated hospitalizations are highest among infants less than 6 months of age, followed by those aged 6-23 months. None of the COVID vaccine products are approved for infants under 6 months of age, so protection can only come from maternal antibodies. The majority (89%) of children and adolescents hospitalized for COVID had not received a dose of the most recently recommended vaccine. These data show why Kennedy's directive to withhold COVID vaccines from children and pregnant women is so absolutely ridiculous. FDA Mandates, Restrictions, and Authorizations Also on June 25, the FDA mandated a label change for COVID vaccines, warning about risk for myocarditis — but did not mention that the risk for myocarditis from COVID infection is greater than the risk for myocarditis after COVID vaccination. In July, more restrictions were placed on COVID vaccines for young children. Moderna's mRNA COVID vaccine, Spikevax, was FDA-approved for everyone aged 65 years or older. Spikevax was also approved for individuals aged 6 months to 64 years old, but only those with at least one medical condition that puts them at increased risk for COVID. Then in August, news reports indicated that Pfizer's COVID vaccine may lose its emergency use authorization for healthy children under the age of 5 years. Although it was expected to be available for children aged 5-11 years, no official announcement has been made. To be clear, if the FDA doesn't renew Pfizer's authorization (or fully approve the vaccine) for children 6 months through 4 years old, healthy children in that age group will have no officially sanctioned option for COVID vaccination. The only way to administer COVID vaccination to healthy children would be to give the Moderna vaccines off-label. If that happens, we could end up having a vaccine shortage. And COVID hasn't gone away. On August 5, CDC's wastewater analysis showed that COVID-19 infections were growing or likely growing in 45 states — indicating a late summer COVID wave. Medical Organizations Step Up to the Plate On August 19, the Vaccine Integrity Project released "From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations." This livestream presentation looked at recently published and publicly available data and found no notable safety or effectiveness issues. Also on August 19, the American Academy of Pediatrics (AAP) issued its own evidence-based immunization schedule for children. For COVID protection, AAP recommends the COVID vaccine for infants and children 6 months through 23 months of age — recognizing that children in this age group are at highest risk for severe COVID. AAP also recommends a single dose of age-appropriate COVID vaccine for all children and adolescents age 2 through 18 years in the following risk groups: Children at high risk for severe COVID Residents of long-term care facilities or other congregate settings Children who've never been vaccinated against COVID Children with household contacts at high risk for severe COVID AAP also recommends that the COVID vaccine be available for children aged 2-18 years who do not fall into these risk groups, but whose parent or guardian desires them to have the protection of the vaccine. AAP recommends that the most updated version of the COVID-19 vaccine available should be used. We can likely expect more medical organizations to issue recommendations based on this new Vaccine Integrity Project review. Concern About the Integrity of Future COVID Vaccination Recommendations According to the ACIP website, another ACIP meeting is planned for August/September, but no date is currently given. We can only hope there will be a truly evidence-based vote on the new-formula COVID vaccines — but I'm not optimistic. On July 31, HHS Secretary Kennedy removed ACIP liaisons from the vaccine work groups. These work groups review vaccine data and develop recommendations that are then presented to ACIP at the public meetings for vote. Now, the work groups are populated only with Kennedy's new ACIP members — most of whom have a proven history of bias against vaccines — and CDC staff that could ostensibly be fired by Kennedy if they don't do what he says. Without liaisons and work groups, we have no way of ensuring that evidence-based science is being applied as these work group recommendations are developed and presented to the full ACIP. To make matters worse, Kennedy recently cut nearly $500 million in research funding aimed at developing better mRNA vaccines; 22 research grants for COVID and flu vaccines were targeted. The reason he gave for these cuts was that vaccines made using this platform were not effective and were unsafe. That's not true. The head of the NIH, Jay Bhattacharya, MD, PhD, offered another explanation for the cancellation. He said the platform wasn't viable because the public doesn't trust it. These cancellations leave us highly vulnerable for the next pandemic — and there will eventually be one. It also puts development of lifesaving mRNA-based cancer treatments at risk. Misinformation Can Be Dangerous On Friday, August 8, a shooter unleashed nearly 500 rounds at CDC buildings in Atlanta. One security officer was killed. The shooter died of a self-inflicted gunshot wound. Authorities found documents in his house expressing discontent with COVID vaccines. Susan Monarez, the new CDC director, was quoted in news reports as saying, "We know that misinformation can be dangerous..." As we also know, Kennedy has been most prominent in spreading misinformation and voicing distrust of vaccines, long before he even became HHS secretary. The case against mRNA technology offered by Kennedy and his new team is unbound by science or evidence. The attack on mRNA vaccines is unscientific foolishness perpetuated by people with a bias against vaccines. They use scientific words in a most unscientific way to create misinformation, vaccine hesitancy, confusion, and mistrust. The recent shooting at CDC is an example of mistrust fueled by vaccine skeptics. Let's not forget it was mRNA vaccines, developed in 1 year through Operation Warp Speed, that saved the world during the COVID pandemic. Billions of doses of mRNA COVID vaccines have been administered worldwide, making them among the most studied vaccines in history. mRNA vaccines are safe and effective. No other vaccine platform can produce vaccines so quickly. HHS Secretary Kennedy's assault on the viability of ACIP and the destruction of our vaccine development infrastructure continue. We still don't have any ACIP recommendations for updated COVID vaccines for fall. We still don't have a date set for the August/September ACIP meeting, and when that meeting date is set, will a vote on COVID vaccines be on that agenda? And if it is, will it be truly evidence-based? The CDC and the HHS secretary are supposed to put forward vaccine policy that can bring health and happiness and prevent death and illness in our country. America's physicians must stand up for our patients, as should everyone who believes in public health. We must push back on misinformation, medical foolishness, and quackery. And the chain of events I have described in this segment is exactly that. Misinformation leads to mistrust in vaccines, mistrust reduces vaccine uptake, and reduced vaccine uptake sickens and kills our patients.
Yahoo
an hour ago
- Yahoo
Was the potentially radioactive shrimp sold in your state? See map.
A recall has been issued for frozen shrimp sold at Walmart in 13 states that may have been contaminated with a radioactive chemical, the Food and Drug Administration said. On Tuesday, Aug. 19, the FDA advised the recall after it detected Cesium-137 (Cs-137), a radioactive chemical "produced by nuclear fission for use in medical devices and gauges," according to the Environmental Protection Agency. The chemical was detected in four U.S. ports across the country and in a sample of breaded shrimp, the FDA stated. "Although testing to date has not confirmed the presence of contamination in any product in commerce, the product appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern," the FDA advised. The FDA is investigating the situation. 82681335007 Which states sold the recalled frozen shrimp? The recalled shrimp were sold in the following 13 states: Alabama Arkansas Florida Georgia Kentucky Louisiana Mississippi Missouri Ohio Oklahoma Pennsylvania Texas West Virginia More recalls: Over 78,000 Jeep Wrangler vehicles recalled. Here's why. Ports that received contaminated shipping containers The four ports where the FDA detected contaminated shipping containers are in the following cities: Los Angeles Houston Miami Savannah, Georgia Which products were recalled? The recall is targeted at 2-pound bags of Great Value brand Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp. Lot codes and best by dates include the following: Lot code: 8005540-1; best by date: 3/15/2027 Lot code: 8005538-1; best by date: 3/15/2027 Lot code: 8005539-1; best by date: 3/15/2027 The shrimp products are processed by PT. Bahari Makmur Sejati, a company in Indonesia doing business as BMS Foods, according to the FDA. What to do if you have recalled shrimp If you have a package of the recalled Walmart shrimp at home, throw it away and do not eat or serve it, the FDA notice says. Distributors and retailers should dispose of the product and refrain from selling it. Anybody who fears they may have been exposed to elevated levels of cesium should contact their medical providers. To submit a complaint or report an adverse reaction, consumers can visit the FDA's Industry and Consumer Assistance portal. PT. Bahari Makmur Sejati placed under an import alert PT. Bahari Makmur Sejati has also been placed on an import alert for chemical contamination, which prevents any of the company's food products from entering the United States until it resolves any conditions that could have caused the exposure. The FDA is working with Indonesian seafood regulatory authorities to investigate the cause of the contamination. What is Cesium-137 (Cs-137) and why is it regulated? Cs-137 is a radioisotope of cesium, meaning it is a chemical element that emits radiation as it breaks down. It is man-made and is produced by nuclear fission, according to the FDA. In the United States, it is used in medical devices and measurement gauges, such as industrial devices that measure the thickness of materials. "It is also one of the byproducts of nuclear fission processes in nuclear reactors and nuclear weapons testing," the EPA stated. Because it is widespread around the globe, trace amounts can be found in the environment, including in soil, food and air, the FDA. Agencies, including the FDA and U.S. Customs & Border Protection, test for, monitor and regulate the presence of the substance due to the risks associated with long-term exposure. Low-level radiation exposure over time can lead to serious health complications, the FDA said. Exposure to Cs-137 alone can cause burns, acute radiation sickness, cancer and death. As a result, the governing agencies restrict potential exposure to lessen the possibility of these long-term impacts. Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@ This article originally appeared on USA TODAY: Which states received the potentially radioactive shrimp? See map.
Yahoo
an hour ago
- Yahoo
US FDA approves Ionis' drug for rare genetic disorder
By Sneha S K and Bageshri Banerjee (Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. Shares of the company were up 1.1% in afternoon trading. The drug, Dawnzera, is approved as a so-called "prophylaxis" to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face. Dawnzera will be available in the United States in the coming days with a list price of $57,462 per dose, the company said. HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis. The drug, chemically known as donidalorsen, prevents HAE attacks by lowering levels of a protein called prekallikrein (PKK) that drives swelling and inflammation. Dawnzera can be self-administered through an under-the-skin injection once every four or eight weeks. The approval was supported by late-stage study results that showed the drug, dosed once every four weeks, reduced monthly attacks by 81% compared to a placebo over 24 weeks. Current FDA-approved therapies for HAE fall into two groups: prophylaxis to prevent attacks and on-demand medicines to treat acute attacks. Other approved prophylactic drugs include Takhzyro, developed by Japan's Takeda Pharmaceutical and Haegarda from CSL Behring. There is a lot of excitement for donidalorsen as patients who are not doing well on existing therapies have an option to switch to Dawnzera, which has a higher efficacy, TD Cowen analyst Yaron Werber said ahead of the approval. Takhzyro, given every two weeks, showed an average of 87% fewer attacks compared to a placebo over 6.5 months in a separate study involving adult and adolescent patients. Werber estimates peak annual sales of Ionis' drug to be $509 million by 2032. Solve the daily Crossword
